Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofitable Anthropic启动自有药物发现项目，攻克大型制药公司认为无利可图疾病

TL;DR

• Anthropic is launching proprietary drug discovery programs targeting neglected diseases, aligning with its nonprofit mission while aiming to improve its AI models through real-world application.
• Novartis CEO Vas Narasimhan estimates AI can reduce drug development timelines from twelve years to seven or eight by cutting information and operational latency, potentially doubling success rates from 8% to 16%.
• The competitive landscape is intensifying as Google DeepMind (via Isomorphic Labs and AlphaFold) and OpenAI (via ChatGPT Health) expand their respective footholds in biomedical research and clinical support.
• Early demonstrations of Anthropic’s "Claude Science" tool highlight significant efficiency gains, such as identifying viral contaminants in minutes and analyzing rare genetic diseases rapidly.

Why It Matters

This shift marks a critical transition where major AI labs are moving beyond providing general tools to actively engaging in high-stakes scientific discovery, particularly in areas traditionally ignored by profit-driven pharmaceutical companies. For researchers and industry leaders, understanding how AI reduces "information latency" offers a tangible metric for ROI in drug development, suggesting that even modest percentage improvements in success rates translate to massive economic and humanitarian impacts. Furthermore, the entry of tech giants into direct therapeutic development signals a consolidation of power in biotech, raising questions about data ownership, regulatory frameworks, and the future role of traditional pharma R&D departments.

Technical Details

• Anthropic’s Approach: Utilization of the "Claude Science" AI tool for preclinical-stage drug development, focusing on neglected diseases. The strategy involves building internal expertise to enhance broader industry tools, leveraging firsthand experience in drug discovery workflows.
• Efficiency Metrics: Analysis of drug development bottlenecks categorizes delays into information latency, operational latency, and biological latency. AI interventions specifically target the first two categories, which constitute approximately 40% of the total twelve-year timeline.
• Performance Benchmarks: Demonstrated capabilities include detecting viral contamination in under a minute (previously missed for a year) and processing 100 rare genetic diseases in under an hour to flag 32 candidates for computational screening.
• Competitive Landscape: Google DeepMind leverages AlphaFold for protein structure prediction and has established Isomorphic Labs for direct drug discovery. OpenAI focuses on clinical integration via ChatGPT Health, connecting medical records and wellness data for patient support.

Industry Insight

Pharmaceutical companies should prioritize partnerships with AI firms that offer specific reductions in information and operational latency, as these areas present the highest immediate efficiency gains compared to biological constraints. Investors and strategists must monitor the convergence of generalist AI models with specialized scientific domains, as companies like Anthropic and DeepMind are blurring the lines between software providers and therapeutic developers. Finally, while AI shows promise in accelerating discovery, stakeholders must remain cautious regarding clinical deployment, as independent experts warn that current models may oversimplify the complex, human-centric realities of healthcare delivery.

TL;DR

• Anthropic宣布启动针对被传统药企忽视的罕见病和未满足医疗需求的药物研发项目，旨在通过非营利使命解决商业利润低的问题。
• 诺华CEO指出AI有望将药物开发周期从12年缩短至7-8年，并通过提升安全性预测使成功率翻倍。
• 行业巨头如DeepMind（Isomorphic Labs）、OpenAI（ChatGPT Health）及Anthropic自身均在加速布局AI制药与临床辅助领域。
• 尽管AI在早期筛选和数据处理上表现显著，但专家警告其在复杂临床环境中的实际应用仍需谨慎，生物验证仍是最大瓶颈。

为什么值得看

本文揭示了AI大模型公司正从单纯的工具提供商转变为直接的药物研发参与者，标志着“AI+Biotech”进入深水区。对于从业者而言，理解Anthropic等非传统药企入局背后的战略逻辑，以及AI在缩短研发周期和提升成功率方面的具体量化预期，有助于把握未来医疗科技的投资与技术风向。

技术解析

• Anthropic的AI制药策略：依托新发布的“Claude Science”工具，Anthropic不仅提供通用能力，还亲自下场进行临床前阶段的药物发现。其核心逻辑是通过处理高难度、低商业回报的疾病数据来训练更强大的AI模型，反哺整个行业。
• 研发效率量化分析：诺华CEO Vas Narasimhan将药物研发延迟分为信息延迟、操作延迟和生物延迟三类。AI主要解决前两类（约占40%时间），通过优化分子设计和安全预测，有望将整体研发时间压缩至7-8年，并将成功率从8%提升至16%。
• 具体应用案例：在演示中，Claude Science在几分钟内识别出UCSF研究人员遗漏一年的病毒污染；并在不到一小时内分析了100种罕见遗传病，筛选出32个计算筛选候选者，展示了极高的数据处理与模式识别效率。
• 竞品技术布局对比：DeepMind通过AlphaFold解决蛋白质结构预测问题，并成立Isomorphic Labs直接制药；OpenAI推出ChatGPT Health整合医疗记录与健康数据；Google DeepMind则探索基于三元护理模式的AI Co-Clinician，强调医生保留最终临床决策权。

行业启示

• 非营利驱动的创新模式：Anthropic选择攻克“无利可图”的疾病，表明AI企业可能通过承担社会责任和非商业目标来建立技术壁垒和行业影响力，这种模式可能成为未来AI在垂直领域落地的新范式。
• AI在制药价值链的定位重构：AI的角色正从辅助工具向核心研发引擎转变。虽然生物验证（临床试验等）难以被AI完全替代，但在靶点发现和分子设计阶段，AI已成为不可或缺的基础设施，传统药企需重新评估其与AI公司的合作或竞争关系。
• 临床落地的谨慎态度：尽管早期数据令人振奋，但牛津大学专家提醒，AI在复杂、混乱的真实世界临床环境中仍存在局限。行业在推进AI诊断和治疗建议时，必须重视人机协作机制（如医生保留最终权威）和数据隐私、伦理合规问题，避免过度炒作。